

Update

REALTECH

On its Way to Double-Digit Margins

Industry: IT Services & Consulting
Country: Germany
Reuters: RTCG.DE
WKN: 700890
Website: www.realtech.de

Current Price: 5,59
High: 10,95
Low: 4,89
Price 52W.: 10,95
Market Cap. (Mill. EUR): 30,1
No. Of Shares (in Mill.): 5,4

Shareholders

Free Float: 50,11%
Daniele Di Croce: 16,44%
Rainer Schmidt: 14,22%
Peter Stier: 13,84%
BWVA: 5,39%


Performance

4 Weeks: -6,0%
13 Weeks: -6,7%
26 Weeks: -31,8%
52 Weeks: -31,4%
YTD: -37,9%

Dividend

| | EUR/Share | in % |
|-------|-----------|------|
| 2009 | 0,20 | 48% |
| 2010 | 0,20 | 45% |
| 2011e | 0,10 | 45% |
| 2012e | 0,13 | 45% |
| 2013e | 0,16 | 45% |

52 Week Share Price History



Analysts

Norbert Kalliwoda
nk@kalliwoda.com

Phone: +49 69 97 20 58 53
www.kalliwoda.com

■ In the third quarter, revenues rose by 7% to €9.5 M (Q3 2010: €10.2 M). Here at last year's figures, the effects of MBOs of the subsidiaries in Spain and Italy have been excluded. The proportion software division versus total sales increased from 27% to 32%. We therefore expect for the future increasing margins. In the third quarter sales of the software segment grew by 27% to €2.5 M (Q3 2010: €3.2 M). Sales of the division Consulting remained with €7M at the same level as the 9month result 2010. In the first nine months 2011 sales in Japan declined, but could recover in the third quarter.

■ The costs of sales have risen faster than revenues. Developments concerning the product theGuard! resulted in high R & D and marketing costs, this led to a decline in EBIT of 96% to €0.04 M (Q3 2010: €0.92 M). Earnings per share were at €-0.03 in the third quarter (Q3 2010: €0.07 M).

■ REALTECH strengthens its collaboration with SAP. The software theGuard! will become integrated into the products "Service Impact Management" and "SAP Business by Design". Regarding these new products we expect in 2012 additional sales revenues and profits based on maintenance services. Although this agreement strengthens the dependence on SAP but for REALTECH it opens an additional potential of 100,000 new customers. In the Consulting segment, the company focuses on the profitable areas. In the software segment the efficiency improves continuously. This is achieved through the integration of the REALTECH subsidiaries into the production processes.

■ After speaking with management, we have adjusted our estimates. In 2011, we expect sales revenues of €39M. Compared to the loss in 2010, we await a slightly positive net income at the end of the fiscal year. Company's product theGuard! should cause a jump in sales of 10% in 2012. We expect double digit margins of the mentioned product. Based on our DCF-Model our fair value is EUR 7.87 per share and we recommend buying the stock.

Key Figures


| EUR m | 2008 | 2009 | 2010 | 2011e | 2012e |
|-------------|-------|------|-------|-------|-------|
| Revenues | 70,8 | 61,7 | 52,5 | 39,5 | 43,4 |
| EBITDA | 8,02 | 3,74 | 5,33 | 1,12 | 5,47 |
| EBIT | 7,02 | 2,64 | 4,36 | 0,12 | 4,47 |
| Net Income | 5,72 | 1,24 | -1,44 | 0,05 | 3,10 |
| EPS | 1,08 | 0,23 | -0,27 | 0,01 | 0,58 |
| BVPS | 5,61 | 5,49 | 4,77 | 4,83 | 5,32 |
| CFPS | 1,29 | 0,47 | -0,09 | 0,20 | 0,77 |
| RoE | 19,6% | 4,3% | -5,7% | 0,2% | 11,0% |
| RoS | 8,1% | 2,0% | -2,7% | 0,1% | 7,1% |
| EBIT margin | 9,9% | 4,3% | 8,3% | 0,3% | 10,3% |

Contents


| | |
|--|-----------|
| 1. Company Performance..... | 3 |
| 2. Share and Shareholder Structure | 4 |
| 3. SWOT Analysis | 4 |
| 4. Financial Analysis..... | 5 |
| 4.1. Profit and Loss..... | 5 |
| 4.2. Balance sheet | 6 |
| 5. Valuation | 7 |
| 5.1. DCF Model | 7 |
| 5.2. WACC..... | 8 |
| 5.3. Fair Value – Sensitivity Analysis..... | 8 |
| 1. CONTACT..... | 9 |
| 2. DISCLAIMER..... | 10 |

1. Company Performance


Revenue Development




Liquid Asset Development




Margin Development




Investment Expenditures



Enterprise Value




Return on Investments and Equity




2. Share and Shareholder Structure

Share Price Development



Source: Dr. Kalliwoda Research, Reuters

Shareholder Structure



Source: Realtech AG

3. SWOT Analysis

Strengths

- Location: Good relationship and located close to SAP
- Market position: Germany's leader in technology consulting
- Market position: Europe's largest provider of service management solutions
- Extensive customer base with well known and prominent customers
- Solid balance sheet and high cash flows
- Sustained revenues in spite of challenging business conditions

Opportunities

- Realtech has the potential to profit from increasing investments in IT.
- The company will develop additional international sales channels through its new partnership with SAP.
- Realtech serves top IT topics such as business intelligence, IT governance, IT security, and service-oriented architectures.

Weaknesses

- Realtech concentrates on the competitive German market
- International product sales are still too low
- IT plays only a subordinate roll in manufacturing production systems. Here we see great potential in the integration of isolated solutions in production IT infrastructure, particularly in the SME sector.

Threats

- Expenses for consulting and IIT services are closely interwoven with macro-economic development
- Realtech is, itself, in competition with SAP
- The IT consulting market is highly competitive which could lead to an increase in price competition.

4. Financial Analysis

4.1. Profit and Loss

| Profit and Loss - REALTECH AG | | | | | |
|--|-----------------|----------------|----------------|---------------|---------------|
| in Mio. EUR | Fiscal Year End | | | | |
| | 2008 | 2009 | 2010 | 2011E | 2012E |
| Revenue | 70,8 | 61,7 | 52,5 | 39,5 | 43,4 |
| Cost of Sales | -43,9 | -40,8 | -32,1 | -21,9 | -23,0 |
| Gross Profit | 26,9 | 20,9 | 20,4 | 17,7 | 20,4 |
| Sales and Marketing Costs | -9,2 | -8,5 | -7,6 | -7,5 | -6,9 |
| Administrative Costs | -7,0 | -6,7 | -5,3 | -5,3 | -5,8 |
| Research and Development Costs | -4,6 | -3,8 | -3,6 | -4,2 | -2,6 |
| Other operating expenses | -1,5 | -1,3 | -1,3 | -1,3 | -1,4 |
| Other operating income | 2,5 | 2,0 | 1,7 | 0,8 | 0,9 |
| Operating Profit | 7,0 | 2,6 | 4,4 | 0,1 | 4,5 |
| Interest Income/Expense | 0,5 | 0,0 | 0,1 | 0,1 | 0,1 |
| Financial Income/Expense | 1,0 | -0,1 | 0,0 | 0,0 | 0,0 |
| Foreign Currency Exchange Gains/Losses | 0,0 | -0,1 | 0,1 | 0,0 | 0,0 |
| Profit Before Tax | 8,5 | 2,4 | 4,5 | 0,2 | 4,6 |
| Income Tax Expense | -2,7 | -1,1 | -2,5 | -0,1 | -1,4 |
| Profit for the Year | 5,8 | 1,3 | 2,0 | 0,2 | 3,2 |
| Attributable to Minority Interests | -0,1 | -0,1 | 0,0 | -0,1 | -0,1 |
| Profit/Loss from Discontinued Operations | 0,0 | 0,0 | -3,4 | 0,0 | 0,0 |
| Profit for the Year | 5,72 | 1,24 | -1,44 | 0,05 | 3,10 |
| Earnings per Share | 1,08 | 0,23 | -0,27 | 0,01 | 0,58 |
| Profit and Loss (Growth) | | | | | |
| Revenue | 13,7% | -7,1% | -21,3% | -31,9% | 5,2% |
| Cost of Sales | 7,0% | -22,3% | -2,3% | -13,5% | 15,4% |
| Gross Profit | 14,9% | -7,8% | -9,9% | -1,6% | -7,6% |
| Sales and Marketing Costs | 4,1% | -5,1% | -21,0% | 1,2% | 8,9% |
| Administrative Costs | 1,1% | -17,4% | -4,7% | 14,6% | -37,3% |
| Research and Development Costs | 16,7% | -15,6% | -2,8% | 6,4% | 6,5% |
| Other operating expenses | 17,9% | -20,0% | -13,0% | -54,6% | 9,7% |
| Other operating income | 6,0% | -62,4% | 65,3% | -97,3% | - |
| Operating Profit | -18,5% | -100,0% | - | 24,5% | 0,0% |
| Interest Income/Expense | - | - | -100,0% | - | - |
| Financial Income/Expense | -100,0% | - | - | -100,0% | - |
| Foreign Currency Exchange Gains/Losses | 18,7% | -71,4% | 84,7% | -95,1% | - |
| Profit Before Tax | 5,5% | -59,3% | 130,1% | -97,4% | - |
| Income Tax Expense | 26,0% | -77,0% | 47,5% | -92,3% | - |
| Profit for the Year | 0,0% | 0,0% | -100,0% | - | 0,0% |
| Attributable to Minority Interests | - | - | - | -100,0% | - |
| Profit/Loss from Discontinued Operations | 26,5% | -78,3% | - | - | - |
| Profit for the Year | 24,1% | -78,7% | - | - | - |
| Profit and Loss (Percentage of Revenue) | | | | | |
| Revenue | 100,0% | 100,0% | 100,0% | 100,0% | 100,0% |
| Cost of Sales | -68,9% | -64,0% | -50,3% | -55,3% | -53,0% |
| Gross Profit | 38,0% | 33,9% | 38,9% | 44,7% | 47,0% |
| Sales and Marketing Costs | -14,4% | -13,3% | -12,0% | -19,0% | -16,0% |
| Administrative Costs | -11,0% | -10,5% | -8,3% | -13,5% | -13,4% |
| Research and Development Costs | -7,2% | -6,0% | -5,7% | -10,5% | -6,0% |
| Other operating expenses | -2,4% | -2,0% | -2,0% | -3,4% | -3,3% |
| Other operating income | 3,9% | 3,1% | 2,7% | 2,0% | 2,0% |
| Operating Profit | 9,9% | 4,3% | 8,3% | 0,3% | 10,3% |
| Interest Income/Expense | 0,7% | 0,0% | 0,2% | 0,3% | 0,2% |
| Financial Income/Expense | 1,4% | -0,2% | 0,0% | 0,0% | 0,0% |
| Foreign Currency Exchange Gains/Losses | 0,0% | -0,2% | 0,1% | 0,0% | 0,0% |
| Profit Before Tax | 12,0% | 4,0% | 8,6% | 0,6% | 10,5% |
| Income Tax Expense | -3,8% | -1,8% | -4,8% | -0,2% | -3,2% |
| Profit for the Year | 8,2% | 2,2% | 3,8% | 0,4% | 7,4% |
| Attributable to Minority Interests | -0,1% | -0,2% | 0,0% | -0,3% | -0,2% |
| Profit/Loss from Discontinued Operations | 0,0% | 0,0% | -6,5% | 0,0% | 0,0% |
| Profit for the Year | 8,1% | 2,0% | -2,7% | 0,1% | 7,1% |

Dr. Kalliwoda | Research © 2011

4.2. Balance sheet

| Balance Sheet - REALTECH AG | | | | | |
|---|-----------------|-------------|-------------|-------------|-------------|
| In €M | Fiscal Year End | | | | |
| | 2008 | 2009 | 2010 | 2011E | 2012E |
| Assets | | | | | |
| <i>Current Assets</i> | | | | | |
| Trade Receivables | 24,0 | 18,0 | 16,7 | 17,7 | 18,8 |
| Tax Receivables | 0,7 | 0,5 | 3,6 | 0,2 | 0,2 |
| Other Current Assets | 1,1 | 1,2 | 0,7 | 1,2 | 1,2 |
| Other Financial Assets | 1,1 | 0,0 | 0,0 | 0,0 | 0,0 |
| Cash and Cash Equivalents | 5,3 | 7,3 | 6,4 | 7,8 | 9,7 |
| Total Current Assets | 32,2 | 27,0 | 27,4 | 26,9 | 29,9 |
| <i>Non-Current Assets</i> | | | | | |
| Concessions, Industrial Rights and Similar Assets | 0,3 | 0,6 | 0,6 | 0,5 | 0,5 |
| Goodwill | 4,3 | 4,3 | 4,3 | 4,3 | 4,3 |
| Property, Plant and Equipment | 7,5 | 7,5 | 7,2 | 7,3 | 7,3 |
| Technical Equipment and Machines | 0,1 | 0,1 | 0,0 | 0,1 | 0,1 |
| Other Equipment and Office Equipment | 1,6 | 1,5 | 1,3 | 1,5 | 1,5 |
| Advance Payments and Construction in Progress | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| Loans Receivable | 0,1 | 0,0 | 0,0 | 0,1 | 0,1 |
| Deferred Tax Assets | 0,3 | 0,2 | 1,2 | 0,3 | 0,2 |
| Other Non-Current Assets | 0,0 | 0,1 | 0,3 | 0,0 | 0,0 |
| Total Non-Current Assets | 14,2 | 14,3 | 14,9 | 14,1 | 14,0 |
| Total Assets | 46,4 | 41,4 | 42,4 | 41,0 | 43,9 |
| <i>Equity</i> | | | | | |
| Issued Capital | 5,3 | 5,3 | 5,4 | 5,3 | 5,3 |
| Capital Reserves | 13,3 | 13,5 | 11,0 | 13,3 | 13,3 |
| Additional Paid-in Capital | -0,4 | 0,1 | 0,5 | 0,2 | 0,2 |
| Other Comprehensive Income | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| Retained Earnings | 10,3 | 8,9 | 7,5 | 6,1 | 8,7 |
| Non-Controlling Interest | 0,7 | 0,8 | 0,9 | 0,7 | 0,7 |
| Total Equity | 29,2 | 28,6 | 25,3 | 25,6 | 28,2 |
| <i>Non-Current Liabilities</i> | | | | | |
| Deferred Tax Liabilities | 0,5 | 0,4 | 0,4 | 0,4 | 0,4 |
| Total Non-Current Liabilities | 0,5 | 0,4 | 0,4 | 0,4 | 0,4 |
| <i>Current Liabilities</i> | | | | | |
| Trade Payables | 2,3 | 1,9 | 1,5 | 1,5 | 1,5 |
| Income Tax Payables | 1,1 | 0,4 | 6,5 | 1,5 | 1,5 |
| Provisions | 8,8 | 5,7 | 4,0 | 7,0 | 7,0 |
| Other Financial Liabilities | 4,5 | 4,4 | 4,7 | 5,0 | 5,2 |
| Other Liabilities | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| Total Current Liabilities | 16,7 | 12,4 | 16,7 | 15,0 | 15,3 |
| Total Equity and Liabilities | 46,4 | 41,4 | 42,4 | 41,0 | 43,9 |

5. Valuation

5.1.DCF Model

Our valuation of REALTECH utilizes a discounted cash flow model. This has been based on REALTECH's consolidated financial statements.

The valuation is driven by discounting the operating free cash flow calculation to the valuation date. We have calculated a residual value assuming a growth rate of 2% per annum.

/ Discounted Cash Flow-Modell (Basis 11/2011)

| (Mio. EUR) | <i>Phase 1</i> | | | | | |
|--------------------------------------|----------------|--------------|--------------|--------------|--------------|--------------|
| | 2011e | 2012e | 2013e | 2014e | 2015e | 2016e |
| Revenue | 39,54 | 43,38 | 46,31 | 49,49 | 52,94 | 56,69 |
| Rate of Change | -25% | 10% | 7% | 7% | 7% | 7% |
| EBIT | 0,12 | 4,47 | 4,91 | 5,40 | 5,95 | 6,54 |
| Rate of Change | -97% | 3667% | 10% | 10% | 10% | 10% |
| Margin | 0,3% | 10,3% | 10,6% | 10,9% | 11,2% | 11,5% |
| Interest and Income from Investments | 0,08 | 0,10 | 0,10 | 0,10 | 0,10 | 0,10 |
| EBT | 0,20 | 4,57 | 5,01 | 5,50 | 6,05 | 6,64 |
| Tax Expense | -0,07 | -1,37 | -1,50 | -1,65 | -1,81 | -1,99 |
| Tax Rate | 33,0% | 30,0% | 30,0% | 30,0% | 30,0% | 30,0% |
| Depreciation | 1,00 | 1,00 | 0,23 | 0,25 | 0,26 | 0,28 |
| Depreciation Rate | 2,5% | 2,3% | 0,5% | 0,5% | 0,5% | 0,5% |
| Changes in Long Term Provisions | 0,00 | 0,10 | 0,10 | 0,10 | 0,10 | 0,10 |
| Percentage of Revenues | - | 0,2% | 0,2% | 0,2% | 0,2% | 0,2% |
| Change in Working Capital | 0,20 | -0,77 | -0,46 | -0,49 | -0,53 | -0,57 |
| Working Capital Ratio | 0,5% | -18% | -10% | -10% | -10% | -10% |
| Investments | -1,00 | -1,00 | -1,25 | -1,34 | -1,43 | -1,53 |
| Investment Rate | -2,5% | -2,3% | -2,7% | -2,7% | -2,7% | -2,7% |
| Free Cash-Flow | 0,33 | 2,53 | 2,13 | 2,37 | 2,64 | 2,94 |
| Rate of Change | -89% | 669% | -16% | 1% | 1% | 1% |
| Free Cash Flow Margin | 0,8% | 5,8% | 4,6% | 4,8% | 5,0% | 5,2% |

Dr. Kalliwoda | Research © 2011

5.2. WACC

The discount rate was determined using the weighted cost of capital. We assume that the capital structure will not change significantly in the coming years.

WACC Assumptions

Growth Assumptions

| | |
|--------------------------------------|----------|
| Terminal Growth Rate/ Inflation Rate | 2.0% |
| Residual Period | 10 Jahre |
| Residual Period Sales Growth | 3.0% |
| Terminal EBIT margin | +1 BP |

Cost of Equity

| | |
|--------------------------|-------------|
| Long Term Risk Free Rate | 3.5% |
| Market Risk Premium | 6.0% |
| Beta of the Company | 0.95 |
| Cost of Equity | 9.2% |

Cost of Debt

| | |
|----------------------|-------------|
| Pre-tax Cost of Debt | 6.5% |
| Normal Tax Rate | 30.0% |
| Cost of Debt | 4.6% |

| | |
|-----------------|--------------|
| Value of Equity | 41 |
| Value of Debt | 0 |
| Gearing | 0.0% |
| WACC | 9.20% |

Adjustments to the liabilities of the current market interest rate have not been made. The risk-free rate is based on the average yield on 30-year government bonds. The determination of the risk premium follows the Capital Asset Pricing Model (CAPM) and covers the systematic risk (market risk premium). Company-specific risk is based on the performance of the DAX benchmark index.

As a result of the recent turmoil in financial markets and continuing economic uncertainty, we have increased our market risk premium from 5% to 6%. This has increased our WACC from 8.25% to 9.2%. We believe this increase reflects the share price volatility created by market risk as opposed to company specific factors.

5.3. Fair Value – Sensitivity Analysis

We have derived a fair value per share of €7.87. This represents a premium of 41.8% over the current share price of €5.55. Here we demonstrate the modification of terminal value parameters in a sensitivity analysis.

| Sensitivity Analysis | | Market Capitalisation | | | | | Sensitivity Analysis | | per Share | | | | |
|----------------------|------|-----------------------|-------|--------------|-------|-------|----------------------|------|-----------|-------|-------------|-------|-------|
| (Mio. EUR) | WACC | 8.70% | 8.95% | 9.20% | 9.45% | 9.70% | (EUR) | WACC | 8.70% | 8.95% | 9.20% | 9.45% | 9.70% |
| β = 0.95 | | | | | | | β = 0.95 | | | | | | |
| Growth | 1.0% | 41.93 | 41.30 | 40.70 | 40.13 | 39.59 | Growth | 1.0% | 7.97 | 7.85 | 7.74 | 7.63 | 7.53 |
| | 1.5% | 42.33 | 41.66 | 41.03 | 40.43 | 39.87 | | 1.5% | 8.05 | 7.92 | 7.80 | 7.69 | 7.58 |
| | 2.0% | 42.79 | 42.07 | 41.40 | 40.77 | 40.17 | | 2.0% | 8.13 | 8.00 | 7.87 | 7.75 | 7.64 |
| | 2.5% | 43.32 | 42.55 | 41.83 | 41.16 | 40.52 | | 2.5% | 8.24 | 8.09 | 7.95 | 7.82 | 7.70 |
| | 3.0% | 43.95 | 43.11 | 42.33 | 41.60 | 40.92 | | 3.0% | 8.36 | 8.20 | 8.05 | 7.91 | 7.78 |

CONTACT

| | | |
|--|---|--|
| DR. KALLIWODA RESEARCH GmbH | | Rüsterstraße 4a 60325 Frankfurt Tel.: 069-97 20 58 53 www.kalliwoda.com |
| Primary Research Fair Value Analysis International Roadshows | | |
| Head: Dr. Norbert Kalliwoda E-Mail: nk@kalliwoda.com | CEFA-Analyst; University of Frankfurt/Main; PhD in Economics; Dipl.-Kfm. | <u>Sectors:</u> IT, Software, Electricals & Electronics, Mechanical Engineering, Logistics, Laser, Technology, Raw Materials |
| Sven Bedbur E-Mail: sb@kalliwoda.com | Dipl.-Kfm. Analyst; University of Frankfurt/Main | <u>Sectors:</u> IT Services & Software, Financial Services, Mining & Exploration |
| Emily Haines E-Mail: eh@kalliwoda.com | MSc in Neurobiology; University College London | <u>Sectors:</u> Biotech & Healthcare; Medical Technology Pharmaceutical |
| Michael John E-Mail: mj@kalliwoda.com | Dipl.-Ing. (Aachen) | <u>Sectors:</u> Chemicals, Chemical Engineering, Basic Metals, Renewable Energies, Laser/Physics |
| Dr. Thomas Krassmann E-Mail: tk@kalliwoda.com | Dipl.-Geologist, M.Sc.; University of Göttingen & Rhodes University, South Africa; | <u>Sectors:</u> Raw Materials, Mining, Precious Metals, Gem stones. |
| Maximilian F. Kaessens E-Mail: mk@kalliwoda.com | Bachelor of Science in Business Administration (Babson College (05/2012), Babson Park, MA (US)) | <u>Sectors:</u> Financials, Real Estate |
| Dr. Christoph Piechaczek E-Mail: cp@kalliwoda.com | Dipl.-Biologist; Technical University Darmstadt; Univ. Witten-Herdecke. | <u>Sectors:</u> Biotech & Healthcare; Medical Technology Pharmaceutical |
| Dr. Erik Schneider E-Mail: es@kalliwoda.com | Dipl.-Biologist; Technical University Darmstadt; Univ. Hamburg. | <u>Sectors:</u> Biotech & Healthcare; Medical Technology Pharmaceutical |
| David Schreindorfer E-Mail: ds@kalliwoda.com | MBA, Economic Investment Management; Univ. Frankfurt/Univ. Iowa (US). | <u>Sectors:</u> IT/Logistics; Quantitative Modelling |
| Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com | Dipl.-Geophysicists; University of Frankfurt/Main. | <u>Sectors:</u> Oil, Regenerative Energies, Specialities Chemicals, Utilities |
| Robin-Andreas Braun E-Mail: rab@kalliwoda.com | Junior-Analyst; University of Frankfurt/Main (2012) | <u>Sectors:</u> Support Research and Quantitative Approach |
| Patrick Bellmann E-Mail: pb@kalliwoda.com | Junior-Analyst; WHU - Otto Beisheim School of Management, Vallendar (2012) | <u>Sectors:</u> Support Research and Quantitative Approach |
| Nele Rave E-Mail: nr@kalliwoda.com | Lawyer (University Marburg); German School London. | <u>Legal Advisor</u> |

Also view Sales and Earnings Estimates:

DR. KALLIWODA | RESEARCH on Terminals of
Bloomberg
Thomson Reuters
vwd group
Factset

Analysts of this research:

Dr. Norbert Kalliwoda



1. DISCLAIMER

| | | |
|----------------------|--|-------------------|
| KAUFEN: | Die Aktie wird auf Basis unserer Prognosen auf Sicht von 12 Monaten eine Kursentwicklung von mindestens 10 % aufweisen | BUY |
| AKKUMULIEREN: | Die Aktie wird auf Basis unserer Prognosen auf Sicht von 12 Monaten eine Kursentwicklung zwischen 5% und 10% aufweisen | ACCUMULATE |
| HALTEN: | Die Aktie wird auf Basis unserer Prognosen auf Sicht von 12 Monaten eine Kursentwicklung zwischen 5% und - 5% aufweisen | HOLD |
| REDUZIEREN: | Die Aktie wird auf Basis unserer Prognosen auf Sicht von 12 Monaten eine Kursentwicklung zwischen - 5% und - 10% aufweisen | REDUCE |
| VERKAUFEN: | Die Aktie wird auf Basis unserer Prognosen auf Sicht von 12 Monaten eine Kursentwicklung von mindestens - 10 % aufweisen | SELL |

Additional Disclosure/Erklärung

DR.KALLIWODA | RESEARCH GmbH hat diese Analyse auf der Grundlage von allgemein zugänglichen Quellen, die als zuverlässig gelten, gefertigt. Wir arbeiten so exakt wie möglich. Wir können aber für die Ausgewogenheit, Genauigkeit, Richtigkeit und Vollständigkeit der Informationen und Meinungen keine Gewährleistung übernehmen.

Diese Studie ersetzt nicht die persönliche Beratung. Diese Studie gilt nicht als Aufforderung zum Kauf oder Verkauf der in dieser Studie angesprochenen Anlageinstrumente. Daher rät DR.KALLIWODA | RESEARCH GmbH, sich vor einer Wertpapierdisposition an Ihren Bankberater oder Vermögensverwalter zu wenden.

Diese Studie ist in Großbritannien nur zur Verteilung an Personen bestimmt, die in Art. 11 (3) des Financial Services Act 1986 (Investments Advertisements) (Exemptions) Order 1996 (in der jeweils geltenden Fassung) beschrieben sind. Diese Studie darf weder direkt noch indirekt an einen anderen Kreis von Personen weitergeleitet werden. Die Verteilung dieser Studie in andere internationale Gerichtsbarkeiten kann durch Gesetz beschränkt sein und Personen, in deren Besitz diese Studie gelangt, sollten sich über gegebenenfalls vorhandene Beschränkungen informieren und diese einhalten.

DR.KALLIWODA | RESEARCH GmbH sowie Mitarbeiter können Positionen in irgendwelchen in dieser Studie erwähnten Wertpapieren oder in damit zusammenhängenden Investments halten und können diese Wertpapiere oder damit zusammenhängende Investments jeweils aufstocken oder veräußern.

Mögliche Interessenskonflikte

Weder DR.KALLIWODA | RESEARCH GmbH noch ein mit ihr verbundenes Unternehmen

- a) hält in Wertpapieren, die Gegenstand dieser Studie sind, 1% oder mehr des Grundkapitals;
- b) war an einer Emission von Wertpapieren, die Gegenstand dieser Studie sind, beteiligt;
- c) hält an den Aktien des analysierten Unternehmens eine Netto-Verkaufsposition in Höhe von mindestens 1% des Grundkapitals;
- d) hat die analysierten Wertpapiere auf Grund eines mit dem Emittenten abgeschlossenen Vertrages an der Börse oder am Markt betreut.

Nur mit dem Unternehmen Realtech AG bestehen vertragliche Beziehungen zu DR.KALLIWODA | RESEARCH GmbH für die Erstellung von Research-Studien. Durch die Annahme dieses Dokumentes akzeptiert der Leser/Empfänger die Verbindlichkeit dieses Disclaimers.

DISCLAIMER

The information and opinions in this analysis were prepared by DR. KALLIWODA | RESEARCH GmbH. The information herein is believed by DR. KALLIWODA | RESEARCH GmbH to be reliable and has been obtained from public sources believed to be reliable. With the exception of information about DR. KALLIWODA | RESEARCH GmbH, DR. KALLIWODA | RESEARCH GmbH makes no representation as to the accuracy or completeness of such information.

Opinions, estimates and projections in this report constitute the current judgement of the author as of the date of this analysis. They do not necessarily reflect the opinions, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate, except if research on the subject company is withdrawn. Prices and availability of financial instruments also are subject to change without notice. This report is provided for informational purposes only. It is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction. The financial instruments discussed in this report may not be suitable for all investors and investors must make their own investment decision using their own independent advisors as they believe necessary and based upon their specific financial situations and investment objectives. If a financial instrument is denominated in a currency other than an investor's currency, a change in exchange rates may adversely affect the price or value of, or the income derived from, the financial instrument, and such investor effectively assumes currency risk. In addition, income from an investment may fluctuate and the price or value of financial instruments described in this report, either directly or indirectly, may rise or fall. Furthermore, past performance is not necessarily indicative of future results.

This report may not be reproduced, distributed or published by any person for any purpose without DR. KALLIWODA | RESEARCH GmbH's prior written consent. Please cite source when quoting.